ArticleNoise & health
Analysis of the positive influence of hyperbaric oxygen therapy on the prognosis and hearing control of patients with noise-induced hearing loss.
Article in Noise & health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this study, the research team aimed to explore the therapeutic effectiveness of hyperbaric oxygen therapy (HBOT) for noise-induced hearing loss (NIHL), its influence on patient prognosis, and its impact on hearing to provide valuable clinical evidence.
methodsNinety-four patients with NIHL admitted to The First People's Hospital of Changde City, Hunan, China, from May 2021 to January 2023 were selected for this retrospective analysis. Among them, 43 were given conventional treatment (control group) and 51 were given HBOT (observation group). The clinical efficacy, symptom improvement, and pure-tone hearing thresholds (PTHTs) at different frequencies were detected. All cases were followed up for 12 months to record the NIHL recurrence rates and hearing (hearing threshold), and their quality of life was investigated.
resultsThe observation group had higher total effective rate and excellent rate and lower incidence of insomnia, tinnitus, and other symptoms than the control group (P < 0.05). PTHTs were lower in the observation group than in the control group at different frequencies (P < 0.05). Follow-up analysis showed no notable intergroup difference in the NHL recurrence rate (P > 0.05), but the hearing threshold was lower and the quality of life was better in the observation group than in the control group (P < 0.05).
conclusionsCompared to conventional treatment, HBOT is effective in treating NIHL and can improve the hearing and coagulation function of patients and provide a reliable guarantee for their prognostic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.